List view / Grid view
Filter the results
Marc Baiget-Francesch highlights interesting developments in the field of protein drug design and explains how continual software improvements are speeding up the process.
An experiment with mice has successively blocked the immune system's T cells from killing transplanted cells.
Having worked in antibody research for over 20 years, Gary McLean has seen how the industry has progressed and understands the potential that antibodies have in the future of medicine. Nikki Withers hears how the focus has shifted from discovery to genetic sequence manipulation and how this can be applied…
Protein therapeutics are a major class of biopharmaceuticals and monoclonal antibodies (mAbs) rule this domain. In this article, Dr Nancy Lopez-Anton outlines the key technologies employed in this important therapeutic discovery area; how they have evolved and what obstacles must be navigated to ensure future success.
Application note: Cell line development: accelerating antibody discovery by monitoring titre and glycosylation with the Octet® platform
Cell line development typically includes the screening of thousands of clones to identify the few that are stable, grow as expected and produce high yields of the bioproduct.
A significant hurdle in optimising antibody therapeutics is the screening of successive rounds of large libraries of mutant variants in order to recognise the ideal candidate.
Monoclonal antibodies are used in a wide range of applications, such as basic research, biopharmaceutical development and in vitro diagnostics.
This issue includes an investigation into utilising recombinant antibodies for research, a highlight on protein design using computational methods and an examination of the advances in genomic medicine. Also in the issue are articles on next generation sequencing and upstream bioprocessing.
Researchers have created a vaccine to treat and prevent streptococcal toxic shock syndrome which showed success in mice models.
A tumour-targeted CRISPR gene editing system encapsulated in a nanogel could halt the growth of triple-negative breast cancer.
TSKgel FcR-IIIA-NPR is based on a recombinant FcγIIIa receptor ligand immobilized on a non-porous polymer particle. It allows fast assessment of biologic activity of monoclonal antibodies.
Researchers have discovered a subtype of immune cells that contribute to allergic reactions and anaphylaxis, providing a drug target.